Glucagon Control on Food Intake and Energy Balance
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Glucagon exerts pleiotropic actions on energy balance and has emerged as an attractive target for the treatment of diabetes and obesity in the last few years. Glucagon reduces body weight and adiposity by suppression of appetite and by modulation of lipid metabolism. Moreover, this hormone promotes weight loss by activation of energy expenditure and thermogenesis. In this review, we cover these metabolic actions elicited by glucagon beyond its canonical regulation of glucose metabolism. In addition, we discuss recent developments of therapeutic approaches in the treatment of obesity and diabetes by dual- and tri-agonist molecules based on combinations of glucagon with other peptides. New strategies using these unimolecular polyagonists targeting the glucagon receptor (GCGR), have become successful approaches to evaluate the multifaceted nature of glucagon signaling in energy balance and metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationPhysiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498 · cited 1×
“of various products from the proglucagon gene depend on posttranslational modifications by specific prohormone convertases (PC) [11].”
BackgroundThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · cited 1×
“However, additional and novel effects for glucagon, such as modulation of satiety, thermogenesis, energy expenditure, and control of lipid metabolism have more recently been garnering scientific attention [3,17].”
BackgroundThe metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272 · cited 1×
“reported increased hepatic TG secretion following fasting and enhanced susceptibility to hepatosteatosis following exposure to a HFD in the same strain, suggesting that disruption of GCGR signaling impairs the control of fatty acid oxidation during fasting [63].”
BackgroundFibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Conarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Salem, V., Izzi‐Engbeaya, C., Coello, C., Thomas, D. B., Chambers, E. S., Comninos, A. N., Buckley, A., Win, Z., Al‐Nahhas, A., Rabiner, E. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12585 · Cited by 167
Tillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164
Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency
NAIR, K. S. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-5-896 · Cited by 141
Glucagon acts in the liver to control spontaneous meal size in rats
Geary, N., Le Sauter, J., & Noh, U. (1993) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1993.264.1.r116 · Cited by 128 · cited 3×
“portal vein was unable to induce satiety after hepatic vagotomy [22].”
BackgroundInfluentialGault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125 · cited 2×
“single hormones as separate molecules [73,74].”
BackgroundGault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512046 · Cited by 123
Jall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107 · cited 1×
“Remarkable, this tri-agonist displays higher efficiency compared to other approved drugs, and indeed improves additional parameters such as lipid metabolism and hepatic steatosis in different rodent models of obesity [88,89].”
BackgroundDesign of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101
Metabolic effects of glucagon in the Wistar rat
SALTER, J. M. (1960) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/8.5.535 · Cited by 85 · cited 1×
“Moreover, this notion is supported by reports which show that rats treated with glucagon gain less weight and less fat compared to pair-fed rats [38].”
ResultInsulin and glucagon as determinants of body weight set point and microregulation in rats
de Castro, J. M., Paullin, S. K., & DeLugas, G. M. (1978) · Journal of Comparative and Physiological Psychology · doi:10.1037/h0077485 · Cited by 74
Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo
Billington, C. J., Briggs, J. E., Link, J. G., & Levine, A. S. (1991) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1991.261.2.r501 · Cited by 71
Calorigenic action of glucagon
DAVIDSON, I. W. F., SALTER, J. M., & BEST, C. H. (1957) · Nature · doi:10.1038/1801124a0 · Cited by 66 · cited 1×
“, it was reported that glucagon injected subcutaneously increased oxygen consumption in rats [36].”
BackgroundHypothalamic CaMKKβ mediates glucagon anorectic effect and its diet-induced resistance
Quiñones, M., Al-Massadi, O., Gallego, R., Fernø, J., Diéguez, C., López, M., & Nogueiras, R. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.09.014 · Cited by 60
Self-citation
Research works printed but not linked: 63
- 1923, Aqueous extracts of pancreas. III. Some precipitaton reactions to insulin, J. Biol. Chem., 58, 337
- Quesada, 2008, Physiology of the pancreatic alpha-cell and glucagon secretion: Role in glucose homeostasis and diabetes, J. Endocrinol., 199, 5, 10.1677/JOE-08-0290 · DOI · Paper page
- Han, 1986, Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain, J. Neurosci. Res., 16, 97, 10.1002/jnr.490160110 · DOI · Paper page
- Drucker, 1988, Glucagon gene expression in vertebrate brain, J. Biol. Chem., 263, 13475, 10.1016/S0021-9258(18)68261-4 · DOI · Paper page
- Ohneda, 1988, Effect of glicentin-related peptides upon the secretion of insulin and glucagon in the canine pancreas, Tohoku J. Exp. Med., 155, 197, 10.1620/tjem.155.197 · DOI
- Whiting, L., Stewart, K.W., Hay, D.L., Harris, P.W., Choong, Y.S., Phillips, A.R., Brimble, M.A., and Cooper, G.J. (2015). Glicentin-related pancreatic polypeptide inhibits glucose-stimulated insulin secretion from the isolated pancreas of adult male rats. Physiol. Rep., 3. · DOI
- Shi, 2013, Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons, Cell Metab., 18, 86, 10.1016/j.cmet.2013.06.014 · DOI · Paper page
- Schmidt, 2003, Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety, Regul. Pept., 116, 21, 10.1016/S0167-0115(03)00175-7 · DOI
- Schmidt, 1985, Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets, Diabetologia, 28, 704, 10.1007/BF00291980 · DOI · Paper page
- Holst, 1994, Proglucagon processing in porcine and human pancreas, J. Biol. Chem., 269, 18827, 10.1016/S0021-9258(17)32241-X · DOI · Paper page
- Segre, 1993, Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family, Trends Endocrinol. Metab., 4, 309, 10.1016/1043-2760(93)90071-L · DOI · Paper page
- Svoboda, 1994, Relative quantitative analysis of glucagon receptor mRNA in rat tissues, Mol. Cell. Endocrinol., 105, 131, 10.1016/0303-7207(94)90162-7 · DOI
- Kieffer, 1996, Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets, Endocrinology, 137, 5119, 10.1210/endo.137.11.8895386 · doi:10.1210/endo.137.11.8895386 · Paper page
- Schulman, 1957, Effect of glucagon on food intake and body weight in man, J. Appl. Physiol., 11, 419, 10.1152/jappl.1957.11.3.419 · DOI · Paper page
- Penick, 1961, Depression of food intake induced in healthy subjects by glucagon, N. Engl. J. Med., 264, 893, 10.1056/NEJM196105042641801 · DOI · Paper page
- Geary, 2001, Estradiol increases glucagon’s satiating potency in ovariectomized rats, Am. J. Physiol. Regul. Integr. Comp. Physiol., 281, R1290, 10.1152/ajpregu.2001.281.4.R1290 · DOI · Paper page
- Noh, 1991, Hepatic portal infusion of glucagon antibodies increases spontaneous meal size in rats, Am. J. Physiol., 261, R162
- Raben, 1994, Evidence for an abnormal postprandial response to a high-fat meal in women predisposed to obesity, Am. J. Physiol., 267, E549
- Nilsson, 1977, Effect of teasing and sham feeding on plasma glucagon concentration in dogs, Acta Physiol. Scand., 100, 298, 10.1111/j.1748-1716.1977.tb05953.x · DOI
- Weatherford, 1988, Lesion of vagal afferent terminals impairs glucagon-induced suppression of food intake, Physiol. Behav., 43, 645, 10.1016/0031-9384(88)90220-X · DOI
- Inokuchi, 1984, Effect of intracerebroventricularly infused glucagon on feeding behavior, Physiol. Behav., 33, 397, 10.1016/0031-9384(84)90160-4 · DOI
- Banks, 1985, Peptides and the blood-brain barrier: Lipophilicity as a predictor of permeability, Brain Res. Bull., 15, 287, 10.1016/0361-9230(85)90153-4 · DOI · Paper page
- Hoosein, 1984, Identification of glucagon receptors in rat brain, Proc. Natl. Acad. Sci. USA, 81, 4368, 10.1073/pnas.81.14.4368 · DOI · Paper page
- Chan, 1984, Suppression of weight gain by glucagon in obese Zucker rats, Exp. Mol. Pathol., 40, 320, 10.1016/0014-4800(84)90049-2 · DOI
- Bloom, 1987, Glucagonoma syndrome, Am. J. Med., 82, 25, 10.1016/0002-9343(87)90424-4 · doi:10.1016/0002-9343(87)90424-4
- Gelling, 2003, Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice, Proc. Natl. Acad. Sci. USA, 100, 1438, 10.1073/pnas.0237106100 · DOI · Paper page
- Bryce, 1977, Insulin and glucagon: Plasma levels and pancreatic release in the genetically obese Zucker rat, Horm. Metab. Res., 9, 366, 10.1055/s-0028-1093529 · doi:10.1055/s-0028-1093529
- Kim, 2018, Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21, Diabetes, 67, 1773, 10.2337/db17-1502 · DOI · Paper page
- Doi, 1982, Modified metabolic responsiveness to glucagon in cold-acclimated and heat-acclimated rats, Life Sci., 30, 785, 10.1016/0024-3205(82)90614-2 · DOI
- Seitz, 1981, Rapid rise in plasma glucagon induced by acute cold exposure in man and rat, Pflug. Arch. Eur. J. Physiol., 389, 115, 10.1007/BF00582100 · DOI
- Kinoshita, 2014, Glucagon is essential for adaptive thermogenesis in brown adipose tissue, Endocrinology, 155, 3484, 10.1210/en.2014-1175 · DOI · Paper page
- Beaudry, 2019, The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice, Mol. Metab., 22, 37, 10.1016/j.molmet.2019.01.011 · DOI · Paper page
- Atrens, 1993, Glucagon and the paraventricular hypothalamus: Modulation of energy balance, Brain Res., 630, 245, 10.1016/0006-8993(93)90663-8 · DOI
- Billington, 1987, Glucagon stimulation of brown adipose tissue growth and thermogenesis, Am. J. Physiol., 252, R160
- Dicker, 1998, Apparent thermogenic effect of injected glucagon is not due to a direct effect on brown fat cells, Am. J. Physiol., 275, R1674
- Caren, 1960, Glucagon and cholesterol metabolism, Metab. Clin. Exp., 9, 938
- Paloyan, 1961, Glucagon as a regulating factor of plasma lipids, Metab. Clin. Exp., 10, 315
- Guettet, 1991, Effect of chronic glucagon administration on the metabolism of triacylglycerol-rich lipoproteins in rats fed a high sucrose diet, J. Nutr., 121, 24, 10.1093/jn/121.1.24 · DOI
- Caren, 1970, Transfer of plasma lipid to platelets by action of glucagon, Metab. Clin. Exp., 19, 598, 10.1016/0026-0495(70)90016-8 · DOI
- Penhos, 1966, Effect of glucagon on the metabolism of lipids and on urea formation by the perfused rat liver, Diabetes, 15, 740, 10.2337/diab.15.10.740 · DOI · Paper page
- Eaton, 1973, Hypolipemic action of glucagon in experimental endogenous lipemia in the rat, J. Lipid Res., 14, 312, 10.1016/S0022-2275(20)36889-9 · DOI · Paper page
- Guettet, 1988, Effects of chronic glucagon administration on cholesterol and bile acid metabolism, Biochim. Et Biophys. Acta, 963, 215, 10.1016/0005-2760(88)90283-4 · DOI
- Guettet, 1989, Effects of chronic glucagon administration on rat lipoprotein composition, Biochim. Et Biophys. Acta, 1005, 233, 10.1016/0005-2760(89)90042-8 · DOI
- Guettet, 1991, Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats, Lipids, 26, 451, 10.1007/BF02536072 · DOI · Paper page
- Perea, 1995, Physiological effect of glucagon in human isolated adipocytes, Horm. Metab. Res., 27, 372, 10.1055/s-2007-979981 · DOI · Paper page
- Mitchell, 1969, Growth-hormone release by glucagon, Lancet, 1, 289, 10.1016/S0140-6736(69)91041-1 · DOI
- Waldhausl, 1976, ACTH and cortisol responses to glucagon stimulation, J. Clin. Endocrinol. Metab., 43, 675, 10.1210/jcem-43-3-675 · DOI
- Sarcione, 1963, Elevation of plasma epinephrine levels produced by glucagon in vivo, Endocrinology, 72, 523, 10.1210/endo-72-4-523 · DOI
- Pegorier, 1989, Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses. Evidence for a decreased sensitivity of carnitine palmitoyltransferase I to malonyl-CoA inhibition after glucagon or cyclic AMP treatment, Biochem. J., 264, 93, 10.1042/bj2640093 · DOI · Paper page
- Vons, 1991, Regulation of fatty-acid metabolism by pancreatic hormones in cultured human hepatocytes, Hepatology, 13, 1126, 10.1002/hep.1840130620 · DOI · Paper page
- Ontko, 1966, Correlation between concentrations of circulating free fatty acids and ketone bodies, Proc. Soc. Exp. Biol. Med., 121, 319, 10.3181/00379727-121-30768 · DOI
- Dixon, 1969, Hepatic lipid metabolism in experimental diabetes. V. The effect of concentration of oleate on metabolism of triglycerides and on ketogenesis, J. Biol. Chem., 244, 2278, 10.1016/S0021-9258(19)78223-4 · DOI · Paper page
- Gerich, 1975, Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon, N. Engl. J. Med., 292, 985, 10.1056/NEJM197505082921901 · DOI · Paper page
- Schade, 1976, Modulation of fatty acid metabolism by glucagon in man. IV. Effects of a physiologic hormone infusion in normal man, Diabetes, 25, 978, 10.2337/diab.25.10.978 · DOI · Paper page
- Parrilla, 1974, Effect of glucagon: Insulin ratios on hepatic metabolism, Diabetes, 23, 725, 10.2337/diab.23.9.725 · DOI · Paper page
- Genuth, 1973, Constant intravenous insulin infusion in diabetic ketoacidosis, JAMA, 223, 1348, 10.1001/jama.1973.03220120020004 · DOI · Paper page
- Wellman, 1999, Synergistic interactions between fenfluramine and phentermine, Int. J. Obes. Relat. Metab. Disord., 23, 723, 10.1038/sj.ijo.0800920 · DOI
- Tschop, 2016, Unimolecular Polypharmacy for Treatment of Diabetes and Obesity, Cell Metab., 24, 51, 10.1016/j.cmet.2016.06.021 · DOI · Paper page
- Quinones, 2019, Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives, Expert Opin. Drug Discov., 14, 421, 10.1080/17460441.2019.1583642 · DOI
- Clemmensen, 2014, GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet, Diabetes, 63, 1422, 10.2337/db13-1609 · DOI · Paper page
- Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 · DOI · Paper page
- Bhat, 2013, A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties, Biochem. Pharmacol., 85, 1655, 10.1016/j.bcp.2013.03.009 · DOI
- Bhat, 2013, A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice, Diabetologia, 56, 1417, 10.1007/s00125-013-2892-2 · DOI
Cited by
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Ji, L., Jiang, H., An, P., Deng, H., Liu, M., Li, L., Feng, L., Song, B., Han-Zhang, H., Ma, Q., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101088 · Cited by 63
Coskun, T., Wu, Q., Schloot, N. C., Haupt, A., Milicevic, Z., Khouli, C., & Harris, C. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00092-0 · Cited by 57
Metadata
- Authors
- Al-Massadi, O., Fernø, J., Diéguez, C., Nogueiras, R., & Quiñones, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-08-11
- Volume
- 20
- Issue
- 16
- Pages
- 3905
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2967453995
- Cited by
- 88
- References
- 26
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Ministerio de Economia y Competitividad (BFU2015-70664R)
- Xunta de Galicia (RN: 2015-CP080 and 2016-PG057, MQ: ED481B2018/004)
- European Community Seventh Framework Programme (RN: ERC-2011-StG-OBESITY53-281408)
- Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.